A one-stop-shop CRO bringing together innovative platforms, strategic solutions and specialized expertise to drive drug development and advance diverse fields of research.
Policies, Terms & Conditions
03.22.24
Huningue, France – Firalis Molecular Precision (FMP), a CAP-accredited fast-growing Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), is thrilled to announce a collaborative effort with Vizgen, a pioneer in spatial omics technology, to introduce a Grant Program, open to researchers in Europe.
Building upon the success of their first collaborative Grant Program, which resulted in selecting a researcher dedicated to investigating the spatial immune cell organization in tumors of triple negative breast cancer (TNBC) patients before immunotherapy, Vizgen and FMP will be supporting, once again, a winning researcher to advance their research project.
As part of the Grant, FMP will award the selected researcher with exclusive access to MERFISH technology coupled with the cutting-edge MERSCOPE® Platform in FMP’s laboratories, leveraging one of Vizgen’s Predesigned Panels for a single-cell spatial analysis project.
This initiative aims to encourage researchers to harness spatial transcriptomics to improve their understanding of cellular interactions and functional states and to advance treatment development in various therapeutic areas (oncology, neurology, immunology).
“We are excited to partner with Vizgen once more in this Grant Program,” said Dr. Eric Schordan, CSO of Firalis Molecular Precision. “By combining FMP’s expertise in spatial omics data generation and analysis with Vizgen’s cutting-edge technology, we aim to empower researchers to unlock new insights into cellular biology and disease mechanisms.”
The winning researcher will also receive comprehensive data analysis services to derive meaningful insights from their experiments.
The program seeks proposals that demonstrate innovation, impact, and a clear potential to advance their research area.
Eligible researchers interested in applying for the Grant Program can find more information and submit their grant application on firalismolecularprecision.com/grant-program-application-page/
Applications will be evaluated by a panel of experts based on scientific merit, innovation, and potential impact.
The deadline to submit a 300-word abstract is June 30, 2024, and the winner will be notified in September 2024.
About Firalis Molecular Precision
Firalis Molecular Precision (FMP) is a fast-growing CRO & CDMO, providing advanced multi-omics solutions and tailored contract research services to the Life Sciences sector.
With headquarters in Huningue, France, and a presence in Cambridge, Mass., FMP is renowned for its commitment to innovation and excellence.
Leveraging cutting-edge technologies, FMP offers a comprehensive suite of bioanalytical services encompassing biobanking, multiomics-driven analyses (including genomics, proteomics, transcriptomics, lipidomics, and metabolomics), as well as omic data analysis, assay development, and custom in vitro diagnostic (IVD) kit manufacturing.
Our mission is to empower healthcare professionals, researchers, and biopharmaceutical entities with the tools and solutions they need to make progress towards better patient care and a more personalized medicine.
About Vizgen
Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insights into the biological systems that govern human health and disease with spatial context.
The company’s MERSCOPE® Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE® provides transformative insights into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development.
For more information, visit www.vizgen.com.
Share this article on your socials